Jyong Biotech (MENS) vs Organogenesis (ORGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Organogenesis (ORGO) has outperformed Jyong Biotech (MENS) over the past year, losing 69.0% versus a loss of 96.1%. Organogenesis is the larger company by market cap ($166.0 million vs $159.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | ORGO |
|---|---|---|
| Share price | $2.10 | $1.29 |
| Market cap | $159.66M | $165.99M |
| 1-day change | 0.00% | +0.78% |
| YTD return | -46.84% | -75.29% |
| 1-year return | -96.12% | -69.01% |
| 5-year return | — | -88.31% |
| EPS (TTM) | $-0.06 | $-0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $63.00 | $7.08 |
| 52-week low | $1.43 | $1.25 |
| Distance from 52-week high | -96.67% | -81.77% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +55.04% |
| Average volume | 45.61K | 770.59K |
| Shares outstanding | 74.23M | 128.67M |
| Employees | 27 | 854 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORGO has outperformed MENS by 27.1 percentage points over the past year.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Organogenesis
ORGO stock →Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.
Health Care · Biotechnology: Pharmaceutical Preparations · 854 employees
MENS vs ORGO FAQ
Which is bigger, Jyong Biotech or Organogenesis?
Organogenesis (ORGO) is larger, with a market capitalization of $165.99M compared with $159.66M for Jyong Biotech (MENS).
Which stock has performed better over the past year, MENS or ORGO?
ORGO returned -69.01% over the past 12 months, compared with -96.12% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and Organogenesis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.